The Prognostic Value of ASPHD1 and ZBTB12 in Colorectal Cancer: A Machine Learning-Based Integrated Bioinformatics Approach.
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: Publisher full text read in Chrome, Methods and Results: transcriptomic ML analysis of colorectal-cancer samples nominated ASPHD1/ZBTB12 prognostic markers; follow-up qPCR in 64 samples and whole-exome validation in 15 samples. Specific gene-marker associations with experimental validation, but small validation subsets and observational evidence do not establish clinical utility.
Technology: Transcriptomic machine-learning analysis ranked colorectal-cancer prognostic markers, which were checked with qPCR and whole-exome data.
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Transcriptomic machine-learning analysis ranked colorectal-cancer prognostic markers, which were checked with qPCR and whole-exome data.
- Limitation / still unknown
- Publisher full text read in Chrome, Methods and Results: transcriptomic ML analysis of colorectal-cancer samples nominated ASPHD1/ZBTB12 prognostic markers; follow-up qPCR in 64 samples and whole-exome validation in 15 samples. Specific gene-marker associations with experimental validation, but small validation subsets and observational evidence do not establish clinical utility.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.mdpi.com/2072-6694/15/17/4300
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.